Back

Targeting Spike Glycans to Inhibit SARS-CoV2 Viral Entry

Guseman, A. J.; Rennick, L. J.; Nambulli, S.; Roy, C. N.; Martinez, D.; Yang, D. T.; Bhinderwhala, F.; Vergara, S.; Baric, R. S.; Ambrose, Z.; Duprex, W. P.; Gronenborn, A. M.

2022-12-22 biochemistry
10.1101/2022.12.22.521642 bioRxiv
Show abstract

SARS-CoV-2 Spike harbors glycans which function as ligands for lectins. Therefore, it should be possible to exploit lectins to target SARS-CoV-2 and inhibit cellular entry by binding glycans on the Spike protein. Burkholderia oklahomensis agglutinin (BOA) is an antiviral lectin that interacts with viral glycoproteins via N-linked high mannose glycans. Here, we show that BOA binds to the Spike protein and is a potent inhibitor of SARS-CoV-2 viral entry at nanomolar concentrations. Using a variety of biophysical tools, we demonstrate that the interaction is avidity driven and that BOA crosslinks the Spike protein into soluble aggregates. Furthermore, using virus neutralization assays, we demonstrate that BOA effectively inhibits all tested variants of concern as well as SARS-CoV 2003, establishing that glycan-targeting molecules have the potential to be pan-coronavirus inhibitors.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.